- 2 - 
Page 2 of Attachment H 
Mr. Chairman and Members of the Committee, I am Irving S. Johnson, 
Vice President of Research, Lilly Research Laboratories. I have adminis- 
trative responsibility at Lilly for biological research directed toward 
pharmaceutical products for human medicine, including work in recombinant 
DNA research. I am accompanied by Bernard 0. Davis, M.D., Adele Lehman, 
Professor of Bacterial Physiology and Director of the Bacterial 
Physiology Unit, Harvard Medical School. 
Lilly has been engaged in the research, development, production, and 
distribution of pharmaceutical products for many years and of agricultural 
products for a number of years. The company has a strong commitment to 
research and has at present in excess of twenty-six hundred scientists 
and technicians involved in its research and development programs. Their 
activities have made possible the development of a wide variety of 
products which have benefited both human health and agriculture. 
My remarks and comments will be addressed to possible or potential 
occupational hazards which may or may not be involved in industrial scale 
recombinant technology. 
Lilly supports the program of voluntary compliance with the NIH Guide- 
lines for Recombinant DNA Research for non-federal ly funded research. 
Historically, Lilly observed the moratorium which applied to certain types 
of recombinant DNA research, and after the establishment of the NIH Guide- 
lines , has voluntarily complied with them. As you know, the NIH 
Guidelines require approval of all protocols by an Institutional 
[ 438 ] 
